Calidi Biotherapeutics, Inc. · AMEX:CLDI
Calidi Biotherapeutics — Investor Presentation (August 2025)
16 slides from Calidi Biotherapeutics's investor presentation, August 2025
Slide 1: Engineering the Future of Genetic Medicine
Immune Genetic Protection Medicine(s) Engineering the Future of Genetic Medicine Targeting From cancer to other complex diseases, Calidi precisely delivers genetic medicines to sites of disease Self-amplifying selective vector Platform NYSEAM:CLDI Not For Public Distribution
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “
Slide 3: Calidi Pipeline: Evolving the Technology
Calidi Pipeline: Evolving the Technology Candidate Indications Discovery IND enabling Phase I Phase 2 Phase 3 (genetic medicine) NeuroNova Rel/ref glioblastoma SuperNova TNBC, SCCHN, sarcoma RedTail: CLD-401 (IL-15 SA) Multiple solid tumors CLD-501 (undisclosed) Myeloma, autoimmune CLD-601 (undisclo
Slide 4: Upcoming Milestones
Upcoming Milestones RedTail Platform: CLD-401: Open IND CLD-201: Potential for Preclinical data 2H2026 for non-dilutive grant supporting platform relapsed/refractory funding to support utility beyond solid solid tumor intratumoral approach tumors 2H ‘25 1H ‘26 2H ‘26 CLD-401: SITC presentation — C
Slide 5: Our Science: Always Evolving
Our Science: Always Evolving • Calidi pioneered the use of viruses loaded into stem cells, enhancing the efficacy of oncolytic viruses • The stem cell membrane allows for improved tumor homing and NeuroNova/SuperNova: Stem cells protection from immune clearance compared to other approaches loaded wi
Slide 6: Our Science: RedTail
Our Science: RedTail Stepwise creation of the platform: A decade of engineering to create RedTail Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Vaccinia virus Multiple sites for Selection of virus Genetic CLD-401:Systemic New candidates engineered for gene insertion strain with engineering to administra
Slide 7: CLD-401: The First RedTail Lead
CLD-401: The First RedTail Lead Systemic administration Systemic Administration Protected from immune CLD-401 infects other tumor cells clearance CLD-401 Targeted tumor cell CLD-401 lysis and immune priming Tumor cell death Specific Infection of and creation of IL-15 superagonist tumor cell,
Slide 8: CD55 Membrane Expression Creates High Resistance to Human Complement
CD55 Membrane Expression Creates High Resistance to Human Complement And Inhibition of Immune Clearance Virus survival in the presence of Human serum Non-enveloped form 6- High therapeutic potential with a multimodal MOA. Enveloped form Enveloped form + CD55 receptor Chimeric CD55 Overexpression of
Slide 9: Administration of RedTail Virus Eliminates Metastatic Lung Tumors
Administration of RedTail Virus Eliminates Metastatic Lung Tumors One (1) dose (5e6 PFU) was able to decrease and eliminate lung cancer and metastatic tumors into the lung. Control RedTail RedTail Tumor signal: Rainbow (Bioluminescence) Bioluminescence images (tumor burden) were taken 6 days after t
Slide 10: IL-15 Superagonist: Proven Activator of Immunity
IL-15 Superagonist: Proven Activator of Immunity Anktiva (IL-15 superagonist) approved for the treatment of BCG-non-responsive nonmuscle invasive bladder cancer in situ • Drug dosed intravesically in bladder cancer at 400 mcg/kg weekly • S.C dosing in NSCLC is 15 mcg/kg every 3 wks (80-fold lower th
Slide 11: High Levels of IL-15 Superagonist in the Tumor But Not Serum
High Levels of IL-15 Superagonist in the Tumor But Not Serum • Serum concentration in syngeneic murine models is negligible • Tumor concentration is much higher than achievable with systemic delivery IL-15 Superagonist Levels in Tumor vs Serum (pM) • RedTail gene therapy delivers IL-15 superagonist
Slide 12: Enhanced Activity With In Situ IL15 Superagonist: Lung Cancer
Enhanced Activity With In Situ IL15 Superagonist: Lung Cancer RedTail virus with the IL-15 superagonist payload drastically improves treatment efficacy Tumor regression in a preclinical model of breast cancer (EMT6) after one (1) administration of 5e6 PFU viral particles Untreated RedTail RedTail +
Slide 13: Additional Genetic Medicine Payloads And Enhanced Targeting
Additional Genetic Medicine Payloads And Enhanced Targeting • RedTail virus is a genetically stable, non-integrating virus with large insertion capacity • Proof-of-concept established with IL-15 superagonist – High levels of in situ delivery of payload – Enhanced activity in tumor models with payloa
Slide 14: RedTail: Potential to Expand Outside of Oncology
RedTail: Potential to Expand Outside of Oncology Lead: CLD-401 Next-Generations Oncology Precision Oncology and Other Diseases • Envelope and CD55 expression facilitate survival in the Additional Add-ons: complement-rich bloodstream, enabling systemic • Envelope can be used to target other cell type
Slide 15: Capitalization Table
Capitalization Table Securities Outstanding (as of August 8, 2025) Common Stock Equivalents * Common stock outstanding 3,576,446 Warrants (WAEP $11.00) 1,291,539 Warrants ($1,380.00) 111,772 Options (WAEP $88.36) 176,794 Forward Purchase Agreements 5,501 Fully Diluted 5,162,052 * Common stock adjust
Slide 16: Calidi: A Commitment to Using Capital Efficiently
Calidi: A Commitment to Using Capital Efficiently Calidi continues to improve its financial position New management New CEO, CMO, and Board Chairman appointed to drive team brought in value Improving the Debt reduced from >$8M to $1.4M (2Q25); projected to be balance sheet $0.6M by end of 20
Calidi Biotherapeutics — Investor Presentation (August 2025) on 6ix